The 17 most recent market catalysts affecting $SLN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 12, 2026
Corporate Catalyst
Bearish
Impact 60
Silence Therapeutics Reports Third Quarter 2026 Financial Results
Silence Therapeutics reported a net loss of $0.08 per share for the third quarter of 2026. This result is significant because it aligns with FactSet analyst consensus estimates, su…
Oct 21, 2026
Corporate Catalyst
Bearish
Impact 65
HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20
HC Wainwright & Co. downgraded Silence Therapeutics (SLN) from a 'Buy' to a 'Neutral' rating and drastically cut its price target from $75 to $20. This significant revision by a co…
Oct 20, 2026
Market Technicals
Bullish
Impact 65
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone
The filing indicates a divergence in market sentiment and performance. While the CNN Fear and Greed Index signals 'Extreme Fear,' the Nasdaq Composite saw a significant gain, prima…
Oct 20, 2026
Corporate Catalyst
Bearish
Impact 85
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
The filing details specific corporate actions and news that significantly impacted the stock prices of Amazon, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics, and EyePoint. …
Oct 19, 2026
Macro/Central Bank
Bullish
Impact 65
Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
The core of this filing is the significant drop in the NAHB/Wells Fargo Housing Market Index, which fell to 29 in October, missing estimates and marking the lowest reading since Ju…
Oct 19, 2026
Market Technicals
Bullish
Impact 65
12 Health Care Stocks Moving In Monday's Intraday Session
This filing is a summary of intraday stock performance for a selection of healthcare companies, noting both significant gainers and losers. It doesn't disclose any specific corpora…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 95
Why Is Silence Therapeutics Stock Skyrocketing Monday?
Silence Therapeutics (SLN) announced its acquisition by Merck KGaA for $1.3 billion in cash, valuing SLN at $20 per ADS, a 130% premium. This news sent SLN shares skyrocketing, ref…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 92
Silence Therapeutics shares are trading higher after the company announced that it will be acquired by Merck KGaA, Darmstadt, Germany, in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.
This acquisition is a major corporate catalyst, driving Silence Therapeutics shares significantly higher due to the substantial premium offered. For Merck KGaA, it represents a str…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 95
Merck KGaA Agrees To Acquire Silence Therapeutics For $20 Per ADS In Cash
Merck KGaA is acquiring Silence Therapeutics, a clinical-stage biotechnology company specializing in siRNA therapies, for an equity value of approximately $1.3 billion. This all-ca…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Silence Therapeutics Prices Upsized $175M Underwritten Public Offering Of 12,962,963 ADSs At $13.50 Per ADS
This headline signifies a significant capital raise for Silence Therapeutics (SLN), providing substantial funding for its operations, likely R&D or clinical trials. The 'upsized' n…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32
Morgan Stanley analyst Michael Ulz has updated his coverage on Silence Therapeutics, maintaining an 'Overweight' rating and raising the price target from $25 to $32. This action si…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 85
Silence Therapeutics Announces Commencement Of Approximately $150M Underwritten Public Offering Of American Depositary Shares
This headline indicates a significant capital raise for Silence Therapeutics (SLN) through a public offering. While it provides crucial funding for R&D and operational expenses, it…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 95
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
Silence Therapeutics reported 'best-case outcome' results from its Phase 2 SANRECO trial for divesiran, a treatment for polycythemia vera. The drug demonstrated strong efficacy, wi…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
Silence Therapeutics shares are trading higher after the company announced topline results from the Phase 2 SANRECO trial met its primary and secondary endpoints.
The headline signifies a major positive corporate catalyst for Silence Therapeutics (SLN). Meeting both primary and secondary endpoints in a Phase 2 trial is a critical milestone, …
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 92
Silence Therapeutics Says Phase 2 SANRECO Trial Of Divesiran In Polycythemia Vera Met Primary Endpoint, 88% Response Rate vs. 19% For Placebo; Phase 3 Seen Starting 1H 2027
This headline represents a major positive catalyst for Silence Therapeutics (SLN). The 88% response rate for Divesiran compared to 19% for placebo in a Phase 2 trial is highly stat…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate
Silence Therapeutics (SLN) announced Q2 earnings per share of $(0.09), which significantly beat the analyst consensus estimate of $(0.15). This represents a substantial improvement…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.